Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee

Affiliations

• ¹ Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA; Harvard Medical School, Harvard University, Boston, MA, USA. Electronic address: ecliff@bwh.harvard.edu.
• ² Division of Myeloma, Department of Hematology and Hematopoietic cell transplantation, City of Hope National Medical Center, Duarte, CA, USA.
• ³ Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA; Harvard Medical School, Harvard University, Boston, MA, USA.